Old people can now stop worrying as anti-ageing is actually possible.
A new study conducted by Marshall University demonstrated the Na/K-ATPase oxidant amplification loop (NAKL) which is intimately involved in the ageing process and may serve as a target for anti-ageing interventions.
The researchers were also able to successfully demonstrate the therapeutic potential of pNaKtide, a synthetic peptide, in improving impaired physiological functions and disease development.
"I believe that our team has not only implicated the NAKL discovered by our colleague, Dr Zijian Xie, in the ageing process but identified a novel therapeutic target as well as a specific pharmacological strategy to actually slow the ageing process. Although it will be some time before we can test these concepts in human subjects, I am cautiously optimistic that clinical therapeutics will ultimately result," said Joseph I. Shapiro, a researcher on this subject.
The research team conducted a year-long study first focused on ageing mice who were given a western diet to stimulate oxidant stress to antagonize the NAKL. The western diet increased the functional and structural evidence for ageing; however, the introduction of pNaKtide slowed these changes in the mice.
The same results were then replicated when human dermal fibroblasts were exposed to different types of oxidant stress in vitro by stimulating the NAKL, increasing expression of senescence markers, and causing cell injury. With pNaKtide treatment, the researchers demonstrated that the negative attributes associated with ageing were significantly dampened.
"Our data clearly suggest that the Na/K-ATPase oxidant amplification loop is intimately involved in the ageing process and, if confirmed in human studies, might ultimately serve as a therapeutic target," said another researcher, Komal Sodhi.
"If the pNaKtide can be safely used in humans, it might be possible to study the applicability of that specific agent to the problem of clinical ageing," she added.
The study appears in Scientific Reports Journal.
Disclaimer: No Business Standard Journalist was involved in creation of this content
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors


Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share


Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor


Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements


Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
